Coupling Gd‑DTPA with a bispecific, recombinant protein anti‑EGFR‑iRGD complex improves tumor targeting in MRI

Xin,Xiaoyan; Sha,Huizi; Shen,Jingtao; Zhang,Bing; Zhu,Bin; Liu,Baorui

doi:10.3892/or.2016.4712

Coupling Gd‑DTPA with a bispecific, recombinant protein anti‑EGFR‑iRGD complex improves tumor targeting in MRI

Authors:
- Xiaoyan Xin
- Huizi Sha
- Jingtao Shen
- Bing Zhang
- Bin Zhu
- Baorui Liu
View Affiliations

Affiliations: Department of Radiology, Affiliated Drum‑Tower Hospital of Nanjing University Medical School, Nanjing 210008, P.R. China, The Comprehensive Cancer Center of Drum‑Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing 210008, P.R. China, Department of Nuclear Medicine, Affiliated Drum‑Tower Hospital of Nanjing University Medical School, Nanjing 210008, P.R. China
Published online on: March 29, 2016 https://doi.org/10.3892/or.2016.4712
Pages: 3227-3235
Copyright: © Xin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recombinant anti‑epidermal growth factor receptor‑internalizing arginine‑glycine‑aspartic acid (anti‑EGFR single‑domain antibody fused with iRGD peptide) protein efficiently targets the EGFR extracellular domain and integrin αvβ/β5, and shows a high penetration into cells. Thus, this protein may improve penetration of conjugated drugs into the deep zone of gastric cancer multicellular 3D spheroids. In the present study, a novel tumor‑targeting contrast agent for magnetic resonance imaging (MRI) was developed, by coupling gadolinium‑diethylene triamine pentaacetate (Gd‑DTPA) with the bispecific recombinant anti‑EGFR‑iRGD protein. The anti‑EGFR‑iRGD protein was extracted from Escherichia coli and Gd was loaded onto the recombinant protein by chelation using DTPA anhydride. Single‑targeting agent anti‑EGFR‑DTPA‑Gd, which served as the control, was also prepared. The results of the present study showed that anti‑EGFR‑iRGD‑DTPA‑Gd exhibited no significant cytotoxicity to human gastric carcinoma cells (BGC‑823) under the experimental conditions used. Compared with a conventional contrast agent (Magnevist), anti‑EGFR‑iRGD‑DTPA‑Gd showed higher T1 relaxivity (10.157/mM/sec at 3T) and better tumor‑targeting ability. In addition, the signal intensity and the area under curve for the enhanced signal time in tumor, in vivo, were stronger than Gd‑DTPA alone or the anti‑EGFR‑Gd control. Thus, Gd‑labelled anti‑EGFR‑iRGD has potential as a tumor‑targeting contrast agent for improved MRI.

View Figures

View References

1	Weissleder R: Molecular imaging in cancer. Science. 312:1168–1171. 2006. View Article : Google Scholar : PubMed/NCBI
2	Hu F, Joshi HM, Dravid VP and Meade TJ: High-performance nanostructured MR contrast probes. Nanoscale. 2:1884–1891. 2010. View Article : Google Scholar : PubMed/NCBI
3	Moffat BA, Reddy GR, McConville P, Hall DE, Chenevert TL, Kopelman RR, Philbert M, Weissleder R, Rehemtulla A and Ross BD: A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging. 2:324–332. 2003. View Article : Google Scholar
4	Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H and van Dongen GA: Nanobodies targeting the hepatocyte growth factor: Potential new drugs for molecular cancer therapy. Mol Cancer Ther. 11:1017–1025. 2012. View Article : Google Scholar : PubMed/NCBI
5	Garanger E, Boturyn D and Dumy P: Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem. 7:552–558. 2007. View Article : Google Scholar : PubMed/NCBI
6	Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR and Conti PS: MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 6:350–359. 2004. View Article : Google Scholar : PubMed/NCBI
7	Chen X, Tohme M, Park R, Hou Y, Bading JR and Conti PS: Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging. 3:96–104. 2004. View Article : Google Scholar : PubMed/NCBI
8	Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H and Schwaiger M: Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61:1781–1785. 2001.PubMed/NCBI
9	Oliveira S, Heukers R, Sornkom J, Kok RJ, van Bergen En and Henegouwen PM: Targeting tumors with nanobodies for cancer imaging and therapy. J Control Release. 172:607–617. 2013. View Article : Google Scholar : PubMed/NCBI
10	Huang L, Gainkam LO, Caveliers V, Vanhove C, Keyaerts M, De Baetselier P, Bossuyt A, Revets H and Lahoutte T: SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 10:167–175. 2008. View Article : Google Scholar : PubMed/NCBI
11	Vosjan MJ, Perk LR, Roovers RC, Visser GW, Stigter-van Walsum M, van Bergen En, Henegouwen PM and van Dongen GA: Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging. 38:753–763. 2011. View Article : Google Scholar : PubMed/NCBI
12	Haspel N, Zanuy D, Nussinov R, Teesalu T, Ruoslahti E and Aleman C: Binding of a C-end rule peptide to the neuropilin-1 receptor: A molecular modeling approach. Biochemistry. 50:1755–1762. 2011. View Article : Google Scholar : PubMed/NCBI
13	Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF and Ruoslahti E: Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 16:510–520. 2009. View Article : Google Scholar : PubMed/NCBI
14	Hiki S and Kataoka K: Versatile and selective synthesis of 'click chemistry' compatible heterobifunctional poly(ethylene glycol)s possessing azide and alkyne functionalities. Bioconjug Chem. 21:248–254. 2010. View Article : Google Scholar : PubMed/NCBI
15	Hoang B, Lee H, Reilly RM and Allen C: Noninvasive monitoring of the fate of 111In-labeled block copolymer micelles by high resolution and high sensitivity microSPECT/CT imaging. Mol Pharm. 6:581–592. 2009. View Article : Google Scholar : PubMed/NCBI
16	Ishihara T, Maeda T, Sakamoto H, Takasaki N, Shigyo M, Ishida T, Kiwada H, Mizushima Y and Mizushima T: Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules. 11:2700–2706. 2010. View Article : Google Scholar : PubMed/NCBI
17	Sha H, Zou Z, Xin K, Bian X, Cai X, Lu W, Chen J, Chen G, Huang L, Blair AM, et al: Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. J Control Release. 200:188–200. 2014. View Article : Google Scholar
18	Kielar F, Tei L, Terreno E and Botta M: Large relaxivity enhancement of paramagnetic lipid nanoparticles by restricting the local motions of the Gd(III) chelates. J Am Chem Soc. 132:7836–7837. 2010. View Article : Google Scholar : PubMed/NCBI
19	Prudêncio M, Rohovec J, Peters JA, Tocheva E, Boulanger MJ, Murphy ME, Hupkes HJ, Kosters W, Impagliazzo A and Ubbink M: A caged lanthanide complex as a paramagnetic shift agent for protein NMR. Chemistry. 10:3252–3260. 2004. View Article : Google Scholar : PubMed/NCBI
20	Uppal R and Caravan P: Targeted probes for cardiovascular MRI. Future Med Chem. 2:451–470. 2010. View Article : Google Scholar : PubMed/NCBI
21	Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR and Ruoslahti E: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 328:1031–1035. 2010. View Article : Google Scholar : PubMed/NCBI
22	Sugahara KN, Braun GB, de Mendoza TH, Kotamraju VR, French RP, Lowy AM, Teesalu T and Ruoslahti E: Tumor- penetrating iRGD peptide inhibits metastasis. Mol Cancer Ther. 14:120–128. 2015. View Article : Google Scholar :